News Search Results
Jan 08, 2026, 05:27 ET Immortal Dragons Comments on Longevity Regulation and Investment Trends Following FT Podcast Appearance
improving human healthspan. The fund currently supports more than 15 portfolio companies operating across diverse areas of longevity science and biotechnology. In addition to its investment activities, Immortal Dragons promotes longevity education and advocacy through book translation and publishing, translation
More news about: Immortal Dragons
Jan 08, 2026, 05:11 ET Ark Biopharmaceutical Receives China Marketing Authorization for Aizhida for the Treatment of ADHD
including Roche, Genentech, the Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture capital institutions.For more information, please visit:
More news about: Arkbio
Jan 08, 2026, 04:53 ET Ark Biopharmaceutical Receives China Marketing Authorization for Aizhida for the Treatment of ADHD
including Roche, Genentech, the Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture capital institutions.For more information, please visit:
More news about: Arkbio
Jan 08, 2026, 04:00 ET Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMD
MUNICH, Jan. 8, 2026 /PRNewswire/ -- Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA)
More news about: Complement Therapeutics
Jan 08, 2026, 04:00 ET Life Sciences Talent and Consulting Strategist George Quinn Named Partner, Fractional Talent at Slone Partners
that, he was Senior Director of On-Demand & Interim Leadership at Heidrick & Struggles, overseeing key accounts across pharmaceuticals and biotechnology.Earlier in his career, Quinn held progressively senior commercial and leadership roles at Axiom and Medasource, where he served most recently
More news about: Slone Partners
Jan 08, 2026, 03:30 ET STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications
precision oncology strategies.NOTES TO EDITORSAbout STORM TherapeuticsSTORM Therapeutics is a clinical-stage biotechnology company pioneering cellular reprogramming through RNA modifications to treat disease. Its world leading understanding of RNA modifying enzymes (RME)
More news about: STORM Therapeutics
Jan 08, 2026, 03:00 ET TECregen Raises CHF 10 Million in Seed Financing and Appoints Dr. Bo Rode Hansen as Chairman
lifeBASEL, Switzerland, Jan. 8, 2026 /PRNewswire/ -- TECregen, a biotechnology company pioneering thymus regeneration, today announced the successful completion of a CHF 10 million (∼EUR 10.7 million / USD 12.6 million) seed
More news about: TECregen AG
Jan 08, 2026, 03:00 ET Independent Dutch Study Further Validates Merlin CP-GEP Test for Melanoma Prognosis
and www.merlinmelanomatest.com.About SkylineDxSkylineDx is a biotechnology company focused on research and development of molecular diagnostics in oncology, and inflammatory and infectious diseases. SkylineDx uses its expertise
More news about: SkylineDx
Jan 07, 2026, 20:19 ET Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
Calif., Jan. 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that senior management will present
More news about: Kodiak Sciences Inc.
Jan 07, 2026, 16:17 ET Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jan 07, 2026, 16:01 ET AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Jan 07, 2026, 15:04 ET LabConnect Establishes New Global Headquarters in Raleigh-Durham Area
Carolina, strengthening its footprint in the rapidly growing Research Triangle region, a leading center for Contract Research Organizations (CROs), biotechnology, and pharmaceutical companies. The new office will serve as a strategic base for executive leadership, commercial, operational, and technology teams
More news about: LabConnect
Jan 07, 2026, 15:04 ET LabConnect Establishes New Global Headquarters in Raleigh-Durham Area
Carolina, strengthening its footprint in the rapidly growing Research Triangle region, a leading center for Contract Research Organizations (CROs), biotechnology, and pharmaceutical companies. The new office will serve as a strategic base for executive leadership, commercial, operational, and technology teams
More news about: LabConnect
Jan 07, 2026, 11:00 ET Arbele Receives FDA Orphan Drug Designation for ARB1002, an Anti-CDH17 Antibody-Drug Conjugate for the Treatment of Pancreatic Cancer
SEATTLE, Jan. 7, 2026 /PRNewswire/ -- Arbele, a biotechnology company focused on developing innovative targeted cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation
More news about: Arbele
Jan 07, 2026, 10:30 ET Pramana Pharmaceuticals Awarded USD $1 Million from the Alzheimer's Association
global composition-of-matter IP estate.About Pramana PharmaceuticalsPramana Pharmaceuticals Inc. is a near-term clinical-stage biotechnology company developing next-generation oral small-molecule therapies targeting metabolic signaling pathways across neurodegenerative and cardio-metabolic
More news about: Pramana Pharmaceuticals Inc.
Jan 07, 2026, 10:30 ET Pharmaceutical Microfiltration Market worth $9.94 billion by 2030 | MarketsandMarkets™
(Sweden).Browse Adjacent Markets: Biotechnology Market Research Reports & ConsultingRelated Reports:
More news about: MarketsandMarkets
Jan 07, 2026, 10:06 ET A Microscopic Discovery With Massive Implications: Two Physicians Uncover a New Biological Defense Against Microplastics
SARASOTA, Fla., Jan. 7, 2026 /PRNewswire/ -- Quorum Innovations, a biotechnology company founded by physician-scientists Nicholas T. Monsul, MD, and Eva Ann Berkes, MD, today announced growing scientific, medical, and public-policy momentum behind a breakthrough
More news about: QUORUM INNOVATIONS
Jan 07, 2026, 10:00 ET Inimmune Commences Pivotal Phase 2 Allergy Trial of INI-2004 in Allergic Rhinitis Patients
MISSOULA, Mont., Jan. 7, 2026 /PRNewswire/ -- Inimmune Corporation ("Inimmune"), a clinical-stage biotechnology company focused on developing innovative immunotherapies, today announced the start of its pivotal Phase 2 clinical trial evaluating INI-2004 in
More news about: Inimmune Corporation
Jan 07, 2026, 09:07 ET KilgourMD Announces Exclusive Partnership With N1 Life to Bring Peptide-Based Delivery Technology to Scalp Health
/PRNewswire/ -- KilgourMD, known for its clinically-backed approach to scalp health, announced an exclusive partnership with N1 Life, a Stanford spinout biotechnology company pioneering a next-generation peptide carrier platform designed to dramatically enhance the penetration, solubility, and performance of topical
More news about: KilgourMD
Jan 07, 2026, 09:00 ET ProGro BIO Releases New Independent Research
time and again: when the soil performs better, the entire system performs better."About ProGro BIO: ProGro BIO is an agricultural biotechnology company committed to improving soil health, nutrient efficiency, and crop performance through advanced microbial technologies. Rhizol® is designed
More news about: ProGro BIO Inc.
Jan 07, 2026, 08:55 ET Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments
clinical trials and product development programs; difficulties or delays in obtaining regulatory approval; competition from other pharmaceutical or biotechnology companies; market volatility affecting our investment portfolio; our ability to realize expected returns from Scilex and other investments; and
More news about: Oramed Pharmaceuticals Inc.
Jan 07, 2026, 08:50 ET Aspen Neuroscience Appoints Chief Commercial Officer Lisa Johnson-Pratt, M.D. and Welcomes Revati Shreeniwas, M.D., FCCP as Chief Medical Officer to Accelerate Late‑Stage Development and Commercial Readiness
SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Aspen Neuroscience, Inc., a clinical‑stage biotechnology company pioneering autologous regenerative therapies, today announced two executive leadership appointments: Revati Shreeniwas, M.D., FCCP has joined
More news about: Aspen Neuroscience, Inc.
Jan 07, 2026, 08:45 ET Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
LEXINGTON, Mass., Jan. 7, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that
More news about: Curis, Inc.
Jan 07, 2026, 08:31 ET TheWell Bioscience and PeptiGrowth Enter into Marketing Collaboration Agreement to Advance Next-Generation Cell Culture Solutions
MONMOUTH JUNCTION, N.J. and TOKYO, Jan. 7, 2026 /PRNewswire/ -- TheWell Bioscience Inc., a biotechnology company pioneering next-generation animal-free biofunctional hydrogels, and PeptiGrowth Inc., a leader in innovative synthetic peptide growth
More news about: TheWell Bioscience
Jan 07, 2026, 08:30 ET Navigating the Animal Rule in Drug Development with Modeling & Simulation, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks